Abstract 234P
Background
Cancer stem cells (CSCs) are a heterogeneous population of cancer cells with characteristics similar to normal stem cells, including the ability for self-renewal and differentiation. CSCs can differentiate into tumor-supporting cells potentially enabling metastasis, relapse, and chemoresistance. Complex networks involving several transcription factors, such as Nanog, Oct4, SOX2, and various miRNAs, have been identified to regulate CSC properties. The EMT is a process in which epithelial cells change their morphology, lose their polarity and acquire the migratory properties of mesenchymal cells. Many reports have shown that cells undergoing EMT can acquire stem cell-like characteristics and express markers of the EMT. However, the correlation between stemness and EMT is still unclear in oral squamous cell carcinomas.
Methods
Tumor tissues and adjacent clinically normal tissues were obtained from 50 patients with primary oral squamous cell carcinoma (OSCC) and 40 patients with recurrent OSCC. The expression of CSC markers Nanog, SOX2, and OCT4 and EMT markers SLUG and TWIST-1 were analyzed using immunohistochemistry. The mean immunoreactive score (staining intensity x proportion of positive cells) was calculated and compared in both tumor tissue and adjacent tissue. The immunohistochemical expression of these markers was correlated with pathological grade, lymph node metastasis, and AJCC staging of the tumor. Additionally, the expressions of SOX-2 and SLUG were evaluated in human OSCC cell lines using Western blot.
Results
The mean immunoreactive score of Nanog, SOX2, OCT4, SLUG and TWIST-1was higher in tumor tissues compared to adjacent tissue. Likewise, higher expression of both CSC and EMT markers was noted in recurrent OSCC than primary OSCC. High-grade tumors and those showing lymph node metastasis exhibited significantly increased expression of SOX-2, OCT4, and SLUG (p<0.01). Western blot analysis showed higher expression of SOX-2 and SLUG proteins in OSCC cells. Knockdown of SOX-2 and SLUG inhibited the migration and invasion of OSCC cells as demonstrated using transmigration assay.
Conclusions
The present study provides novel insights into the potential association between CSCs and EMT in OSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract